Will laromestrocel (Longeveron) confirm its effect in a larger frailty trial beyond Phase 2b?
Chance it happens
40%Belief the predicted event happens at all — every “yes / by-a-date” outcome added together. “Other” is tracked as its own third slice.
Outcomes
Resolution criteria
A result from a frailty trial larger than Phase 2b for laromestrocel vs a functional primary endpoint. Resolution horizon: 2028-06-30. Source: Longeveron, registry.
Description
Laromestrocel (formerly Lomecel-B) is Longeveron's experimental cell therapy: allogeneic medicinal signaling cells — mesenchymal stem cells taken from the bone marrow of young, healthy donors, grown in culture, and given by IV infusion. "Allogeneic" means one donor's cells are used off-the-shelf in many unrelated patients, rather than harvesting each patient's own. The intended effect is not to treat one disease but to damp down the chronic, low-grade inflammation of aging and nudge tissue repair. The trial this market builds on is Longeveron's Phase 2b aging-frailty study (ClinicalTrials.gov NCT03169231): a randomized, placebo-controlled, dose-finding trial in 148 ambulatory adults (155 enrolled) aged 70–85 who were mildly to moderately frail (Clinical Frailty Scale 5–6). Its primary endpoint was the six-minute walk test — literally how far a person can walk in six minutes, a hard functional measure rather than a lab number. Published in Cell Stem Cell in February 2026, it reported that the treated group walked 63.4 metres further than placebo at nine months (p = 0.0077), in a dose- and time-dependent pattern. Trial registry: https://clinicaltrials.gov/study/NCT03169231 — Published results: https://pubmed.ncbi.nlm.nih.gov/41747733/ A Phase 2b is a mid-size dose-finding study, not the large pivotal trial regulators want before approval — so a positive Phase 2b is promising, not confirmatory. As of mid-2026 no larger (Phase 3) frailty trial for laromestrocel has been registered. In plain words, this market asks: by 30 June 2028, will laromestrocel reproduce this frailty benefit in a trial bigger than Phase 2b, again on a real functional endpoint (walking distance, grip strength, frailty index) rather than only molecular markers? Resolution horizon: 2028-06-30.
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This is a PubMed-indexed Phase 2b trial publication on laromestrocel for aging frailty in Cell Stem Cell. It is directly relevant because it reports the Phase 2b evidence base that any larger confirmatory frailty trial would need to replicate or extend on a functional primary endpoint.
This is a ClinicalTrials.gov record for Longeveron’s Phase IIb frailty trial of laromestrocel/Longeveron Mesenchymal Stem Cells. It is directly relevant because the prediction asks whether the Phase IIb signal will later be confirmed in a larger frailty trial beyond Phase IIb.
This appears to be a journal publication describing the randomized Phase 2b laromestrocel trial in aging frailty. It is directly relevant because it establishes the Phase 2b efficacy/safety baseline that any larger confirmatory frailty trial beyond Phase 2b would need to reproduce on a functional primary endpoint.
This appears to be a news article describing positive frailty-trial results for laromestrocel, likely referring to Phase 2b evidence in age-related frailty. It does not resolve the prediction, but it is relevant background because favorable earlier-stage functional-endpoint results affect the outlook for confirmation in a larger post-Phase-2b trial.